Scientific Sessions 2024  /  Bridging the Gaps in the Management of Cardiac Amyloidosis - Where are we in 2024?  /  ATTR Genetic Screening and Subsequent Management in Underrepresented Populations-Bridging the Gap 10 minutes

American Heart Association

  84
  0

Final ID:

ATTR Genetic Screening and Subsequent Management in Underrepresented Populations-Bridging the Gap 10 minutes

  • Ruberg, Frederick  ( Boston University , Boston , Massachusetts , United States )
  • Gillmore, Julian  ( UCL Centre for Amyloidosis , London , United Kingdom )
    • Author Disclosures:
    Frederick Ruberg: DO have relevant financial relationships ; Consultant:Attralus:Active (exists now) ; Research Funding (PI or named investigator):Akcea:Past (completed) ; Research Funding (PI or named investigator):Alnylam:Past (completed) ; Research Funding (PI or named investigator):Anumana:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) | Julian Gillmore: DO have relevant financial relationships ; Consultant:Alnylam, ATTRalus, AstraZeneca, Bridgebio, Lycia, Intellia, Pfizer:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Bridging the Gaps in the Management of Cardiac Amyloidosis - Where are we in 2024?

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Role of Artificial Intelligence in Screening and Diagnosis of Cardiac Amyloidosis in a Diverse Patient population 10 minutes

Grogan Martha, Harmon David

Novel Therapies in the Management of Cardiac Amyloidosis and Access to Care

Falk Rodney, Kittleson Michelle, Cuddy Sarah

More abstracts from these authors:
Discussant: Danon Disease Phase 1 RP-A501

Gillmore Julian, Taylor Matthew, Adler Eric

Building a Multidisciplinary Amyloidosis Program

Ruberg Frederick, Fontana Marianna

You have to be authorized to contact abstract author. Please, Login
Not Available